ONK Therapeutics Ltd
https://www.onktherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ONK Therapeutics Ltd
Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.
Intellia Flags In Vivo CRISPR Knockout Platform As Key Priority For 2023
After ending 2022 with more than $1bn in cash, the US firm is keen to validate its in vivo approach to gene therapy with investigational new drug applications and pivotal trials lined up for two core rare disease programs.
5 Dealmaking Trends To Watch In 2022
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies
Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice